The long-term efficacy of chemotherapy in patients with acute myeloid leukemia (AML) has been significantly improved in recent years. The combination of anthracycline plus cytarabine (Ara-C) has been a standard induction regimen for patients with AML. However, the optimal consolidation therapy after induction chemotherapy has not reached a consensus. The FLAG regimen consisting of fludarabine and high-dose cytarabine combined with G-CSF which is one of the first-line consolidation treatment options for relapsed and refractory AML. This study conducted a retrospective analysis of the intensive treatment of AML with the FLAG regimen from January 2007 to May 2018 in our hospital to evaluate the efficacy of the FLAG regimen. To provide the basis for the choice and timing of treatment for patients with AML treated with the FLAG regimen.
Study Type
OBSERVATIONAL
Enrollment
60
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
RECRUITINGOverall survival
For evaluating the FLAG effect, OS was defined from consolidation randomization to death from any cause (censored at last contact).
Time frame: 3 years
Relapse-free survival
Relapse Free Survival defined as the time from onset of FLAG treatment for AML to the first event (death or relapse).
Time frame: 2 years
Severe adverse events
Severe adverse events during consolidation treatment
Time frame: 45 days
Complete Remission Rate
Time frame: 2 months
Event-Free Survival Rate
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.